MHRA Looks To Triptans, Anti-Hypertensives As Next Switch Categories
This article was originally published in The Tan Sheet
Executive Summary
The UK's Medicines & Healthcare products Regulatory Agency expects to review an application to reclassify a triptan for migraine from Prescription Only Medicine (POM) to Pharmacy (P) status in the next year and a half
You may also be interested in...
Non-Rx chlamydia drug
U.K. consumers will be able to obtain an oral antibiotic for the treatment of chlamydia without a prescription, the Medicines and Healthcare products Regulatory Agency announces Aug. 6. Actavis' Clamelle (azithromycin) will be available to consumers 16 years old and up if they test positive for the infection and have no symptoms, as well as for their sexual partners, MHRA says. Actavis is developing training materials and a formal launch plan for Clamelle's switch from prescription only to pharmacy status, which is similar to behind-the-counter in the U.S. In March, MHRA approved urinary tract infection drug Cystobid 100 mg (nitrofurantoin) - Procter & Gamble's Macrobid in the U.S. - for pharmacy sale in a move consistent with the agency's plan to move more POM products into the P class to reduce health care costs, promote self-care and expand the role of pharmacists in treatment (1"The Tan Sheet" March 10, 2008, In Brief and 2"The Tan Sheet" June 6, 2005, p. 4)...
Non-Rx chlamydia drug
U.K. consumers will be able to obtain an oral antibiotic for the treatment of chlamydia without a prescription, the Medicines and Healthcare products Regulatory Agency announces Aug. 6. Actavis' Clamelle (azithromycin) will be available to consumers 16 years old and up if they test positive for the infection and have no symptoms, as well as for their sexual partners, MHRA says. Actavis is developing training materials and a formal launch plan for Clamelle's switch from prescription only to pharmacy status, which is similar to behind-the-counter in the U.S. In March, MHRA approved urinary tract infection drug Cystobid 100 mg (nitrofurantoin) - Procter & Gamble's Macrobid in the U.S. - for pharmacy sale in a move consistent with the agency's plan to move more POM products into the P class to reduce health care costs, promote self-care and expand the role of pharmacists in treatment (1"The Tan Sheet" March 10, 2008, In Brief and 2"The Tan Sheet" June 6, 2005, p. 4)...
Non-Rx chlamydia drug
U.K. consumers will be able to obtain an oral antibiotic for the treatment of chlamydia without a prescription, the Medicines and Healthcare products Regulatory Agency announces Aug. 6. Actavis' Clamelle (azithromycin) will be available to consumers 16 years old and up if they test positive for the infection and have no symptoms, as well as for their sexual partners, MHRA says. Actavis is developing training materials and a formal launch plan for Clamelle's switch from prescription only to pharmacy status, which is similar to behind-the-counter in the U.S. In March, MHRA approved urinary tract infection drug Cystobid 100 mg (nitrofurantoin) - Procter & Gamble's Macrobid in the U.S. - for pharmacy sale in a move consistent with the agency's plan to move more POM products into the P class to reduce health care costs, promote self-care and expand the role of pharmacists in treatment (1"The Tan Sheet" March 10, 2008, In Brief and 2"The Tan Sheet" June 6, 2005, p. 4)...